Efficacy of Early Rhythm Control in AF With TR Patients (TRAF)
研究概览
地位
详细说明
Atrial fibrillation and tricuspid regurgitation frequently coexist in clinical practice. Atrial fibrillation may promote right atrial enlargement and tricuspid annular dilatation, which can aggravate functional tricuspid regurgitation over time. Conversely, significant tricuspid regurgitation may further increase right-sided volume overload, worsen atrial remodeling, and contribute to the persistence or progression of atrial fibrillation. This bidirectional relationship may lead to heart failure, thromboembolic events, and an increased need for tricuspid valve intervention.
Although early rhythm control has been shown to improve cardiovascular outcomes in selected patients with atrial fibrillation, its clinical benefit in patients with concomitant tricuspid regurgitation has not been well established. In particular, it remains uncertain whether maintaining sinus rhythm at an early stage can slow the progression of right-sided cardiac remodeling, reduce heart failure events, and improve long-term prognosis in this population.
This study is designed to evaluate the prognostic impact of early rhythm control compared with usual care in patients with atrial fibrillation and tricuspid regurgitation. The primary endpoint will be a composite of cardiac death, heart failure admission, stroke, and tricuspid valve surgery. By comparing these clinically meaningful outcomes between the two treatment strategies, this study aims to clarify whether early rhythm control should be considered as an active therapeutic approach in patients with atrial fibrillation complicated by tricuspid regurgitation.
The study will use retrospectively collected data from patients diagnosed with atrial fibrillation and tricuspid regurgitation between January 1, 2013 and December 31, 2023. Clinical outcomes will be assessed during this observation period.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Ju Youn Kim, Ph.D
- 电话号码:82+ 10-5482-7307
- 邮箱:kzzoo921@gmail.com
学习地点
-
-
Seoul
-
Seoul、Seoul、韩国、06351
- 招聘中
- Samsung Medical Center
-
接触:
- Ju Youn Kim, Ph.D
- 电话号码:82+ 2-3410-3419
- 邮箱:kzzoo921@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
The investigator emulated a sequential target trial comparing early rhythm control with usual care among patients with atrial fibrillation and tricuspid regurgitation, using data from the Korean National Health Insurance Service (K-NHIS) claims database.
The K-NHIS database represents the entire population of Korea. The K-NHIS database covers the total population of Korea. The NHIS database includes information on all individuals in Korea, such as demographics, diagnosis codes based on the International Classification of Diseases, 10th Revision (ICD-10), procedures, prescriptions (coded by ATC codes), utilization of healthcare services, and mortality linked to national statistics. The investigator further linked these data with the National Health Screening Program, which provides biennial standardized health examination results, including laboratory measurements such as serum creatinine and hemoglobin, using anonymized individual identifiers.
描述
Inclusion Criteria:
- Patients with concomitant atrial fibrillation and tricuspid regurgitation.
Exclusion Criteria:
- Patients with a history of valvular surgery
- Patients with congenital heart disease
- Patients with primary pulmonary hypertension
- Patients with CIED implantation prior to the diagnosis of tricuspid regurgitation
- Patients diagnosed with TR only after the initiation of rhythm control therapy for AF
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
early rhythm control group
Patients who received rhythm control therapy(include catheter ablation, cardioversion, anti-arrhythmic drugs) within 2 years of new-onset atrial fibrillation
|
flecainide, propafenone, pilsicainide, sotalol, amiodarone, dronedarone
Direct-current cardioversion may be performed to acutely restore sinus rhythm, particularly in patients with persistent atrial fibrillation or symptomatic rhythm deterioration.
Catheter ablation may be considered as a more definitive rhythm-control strategy to reduce atrial fibrillation burden and maintain sinus rhythm over the long term.
|
|
Usual care group
Patients who received usual care include rate control therapy without early rhythm control intervention within 2 years of new-onset atrial fibrillation
|
General management without atrial fibrillation rhythm control treatment.(Observation
without additional medication, or heart rate control treatment if necessary)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
A composite of cardiac death, hospitalization for heart failure, stroke, and tricuspid valve surgery
大体时间:From January 1, 2013 to December 31, 2023
|
The incidence rate of the major clinical events Major clinical event is;
|
From January 1, 2013 to December 31, 2023
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
All cause death
大体时间:From January 1, 2013 to December 31, 2023
|
The incidence rate of all-cause death during the observation period.
|
From January 1, 2013 to December 31, 2023
|
|
Cardiac death
大体时间:From January 1, 2013 to December 31, 2023
|
The incidence rate of cardiac death during the observation period.
|
From January 1, 2013 to December 31, 2023
|
|
Hospitalization for heart failure
大体时间:From January 1, 2013 to December 31, 2023
|
The incidence rate of hospitalization for heart failure during the observation period.
(admission due to worsening signs or symptoms of heart failure requiring medical treatment, including intravenous diuretics, inotropes, vasodilators, or other heart failure-directed therapy)
|
From January 1, 2013 to December 31, 2023
|
|
Stroke
大体时间:From January 1, 2013 to December 31, 2023
|
The incidence rate of stroke during the observation period.
(new neurological deficit of presumed vascular origin, including ischemic or hemorrhagic stroke, confirmed by clinical evaluation and/or brain imaging)
|
From January 1, 2013 to December 31, 2023
|
|
Tricuspid valve surgery
大体时间:From January 1, 2013 to December 31, 2023
|
The incidence rate of tricuspid valve surgery during the observation period.
(surgical or transcatheter intervention for tricuspid valve disease, including tricuspid valve repair or replacement)
|
From January 1, 2013 to December 31, 2023
|
|
Pacemaker implantation
大体时间:From January 1, 2013 to December 31, 2023
|
The incidence rate of pacemaker implantation during the observation period.
(new implantation of a permanent pacemaker during the observation period, including single-chamber or dual-chamber pacemaker implantation, when performed for clinically indicated bradyarrhythmia or conduction disease)
|
From January 1, 2013 to December 31, 2023
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- SMC 2025-05-075-1
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.